A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).

被引：0

作者：

Gutierrez, Martin

Goy, Andre

Byrd, John C.

Flynn, Joseph M.

Sorensen, Morten

Brown, Peter

Gabrail, Nashat Y.

Savona, Michael

Flinn, Ian

Baz, Rachid C.

Shah, Bijal D.

Stone, Richard M.

Jacobsen, Eric

Kukreti, Vishal

Tiedemann, Roger E.

Rashal, Tami

Mirza, Mansoor Raza

Shacham, Sharon

Kauffman, Michael

Kuruvilla, John

机构：

[1] John Theurer Canc Ctr, Hackensack, NJ USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] Rigshosp, DK-2100 Copenhagen, Denmark

[4] KAT, Finsen Ctr, H S Rigshosp, Haematol Dept 4241, Copenhagen, Denmark

[5] Gabrail Canc Ctr, Canton, OH USA

[6] Tennessee Oncol, Nashville, TN USA

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Dana Farber Canc Ctr Inst, Boston, MA USA

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[13] Karyopharm Therapeut, Newton, MA USA

[14] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8518

引用

页数：1